National Academies Press: OpenBook
« Previous: 5 Legal Issues in Collaborations
Suggested Citation:"6 Financial Challenges." Institute of Medicine. 2012. Facilitating Collaborations to Develop Combination Investigational Cancer Therapies: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/13262.
×

6

Financial Challenges

Several participants noted financial challenges linked to cancer drug development, including the expense of developing knockout1 and other animal models, RNA sequence libraries, and creating enough study drug to test, which is especially problematic for biologics. Most of these challenges pertain to combination therapy development as well as drug development in general. Dr. Stern noted that investigators rely on RNA libraries to do screening, but those libraries are often prohibitively expensive and suggested the federal government could become involved in supporting those libraries.

Dr. Doroshow pointed out that standard grants from the National Institutes of Health (NIH) do not provide funding for validating assays, despite the growing importance of patient selection assays in clinical trials.

Dr. June noted that clinical trials for many immunotherapies are expensive because the cells need to be manufactured, “so we are paying for both the cost of the drug, which is a biologic or a cell, and the standard clinical trial costs. Raising funds is a very large challenge and the NCI grants don’t cover these kinds of trials. It requires multiple kinds of support from grants, foundations, and philanthropy.” He pointed out that cell therapies are not necessarily more expensive than antibody therapies

image

1 A knockout mouse is a laboratory mouse in which researchers have inactivated, or “knocked out,” an existing gene by replacing it or disrupting it with an artificial piece of DNA, in order to better understand how a similar gene may cause or contribute to disease in humans.

Suggested Citation:"6 Financial Challenges." Institute of Medicine. 2012. Facilitating Collaborations to Develop Combination Investigational Cancer Therapies: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/13262.
×

because they do not have to be given for as long a period of time. “The cost of goods for us to manufacture one of these cell therapy infusions is $15,000, which is less than 3 months of antibody therapy. Right now, patients are often getting antibodies for their lifespan. If you have a self-replicating cell that can continue to make antibodies, the cells may actually in the end be more cost-effective,” Dr. June said.

Suggested Citation:"6 Financial Challenges." Institute of Medicine. 2012. Facilitating Collaborations to Develop Combination Investigational Cancer Therapies: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/13262.
×
Page 53
Suggested Citation:"6 Financial Challenges." Institute of Medicine. 2012. Facilitating Collaborations to Develop Combination Investigational Cancer Therapies: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/13262.
×
Page 54
Next: 7 Regulatory Issues »
Facilitating Collaborations to Develop Combination Investigational Cancer Therapies: Workshop Summary Get This Book
×
Buy Paperback | $38.00 Buy Ebook | $30.99
MyNAP members save 10% online.
Login or Register to save!
Download Free PDF

Advances in biomedical research have increased our understanding of the complex nature of disease and the interaction of multiple molecular pathways involved in cancer. Combining investigational products early in their development is thought to be a promising strategy for identifying effective therapies. The IOM's National Cancer Policy Forum held a workshop to discuss challenges and identify potential solutions to improve collaboration and advance the development of combination investigational cancer therapies.

  1. ×

    Welcome to OpenBook!

    You're looking at OpenBook, NAP.edu's online reading room since 1999. Based on feedback from you, our users, we've made some improvements that make it easier than ever to read thousands of publications on our website.

    Do you want to take a quick tour of the OpenBook's features?

    No Thanks Take a Tour »
  2. ×

    Show this book's table of contents, where you can jump to any chapter by name.

    « Back Next »
  3. ×

    ...or use these buttons to go back to the previous chapter or skip to the next one.

    « Back Next »
  4. ×

    Jump up to the previous page or down to the next one. Also, you can type in a page number and press Enter to go directly to that page in the book.

    « Back Next »
  5. ×

    Switch between the Original Pages, where you can read the report as it appeared in print, and Text Pages for the web version, where you can highlight and search the text.

    « Back Next »
  6. ×

    To search the entire text of this book, type in your search term here and press Enter.

    « Back Next »
  7. ×

    Share a link to this book page on your preferred social network or via email.

    « Back Next »
  8. ×

    View our suggested citation for this chapter.

    « Back Next »
  9. ×

    Ready to take your reading offline? Click here to buy this book in print or download it as a free PDF, if available.

    « Back Next »
Stay Connected!